Inactive Instrument

PRIA ACQU

Equities

PMGM

US74275N1028

Priveterra Acquisition Corp. Reports Earnings Results for the Second Quarter Ended June 30, 2021

August 16, 2021 at 06:36 am EDT

Priveterra Acquisition Corp. announced earnings results for the second quarter ended June 30, 2021. For the second quarter, the company announced operating loss was USD 398,443. Net loss was USD 4.025 million. For the half year, operating loss was USD 599,306. Net income was USD 2.294 million.

Latest news about PRIA ACQU

AEON Biopharma Completes Business Combination With Priveterra Acquisition; Shares Slump	23-07-24	MT
Priveterra Acquisition Completes Merger With AEON Biopharma	23-07-21	MT
Priveterra Acquisition Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-07-21	CI
Priveterra Acquisition Corp.(NasdaqCM:PMGM) dropped from NASDAQ Composite Index	23-07-21	CI
AEON Biopharma, Inc. completed the acquisition of Priveterra Acquisition Corp. from Priveterra Sponsor, LLC, Empyrean Capital Overseas Master Fund, Ltd., managed by Empyrean Capital Partners, LP, Medy-Tox Inc., Daewoong pharmaceutical Co.,Ltd, Strathspey Crown LLC and others in a reverse merger transaction.	23-07-20	CI
Priveterra Acquisition Gets New York Stock Exchange Approval for Listing of AEON Biopharma Stock, Warrants	23-07-18	MT
Priveterra Acquisition to Transfer Stock Listing to NYSE After Completing Business Combination	23-07-12	MT
Top Premarket Decliners	23-07-05	MT
Priveterra Acquisition Corp. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-17	CI
Priveterra Acquisition Corp. announced that it has received $1 million in funding	23-04-26	CI
Priveterra Acquisition Corp. Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-22	CI
Priveterra Acquisition Corp. Auditor Raises 'Going Concern' Doubt	23-02-21	CI
AEON Biopharma, Inc. entered into a definitive business combination agreement to acquire Priveterra Acquisition Corp. from Priveterra Sponsor, LLC, Empyrean Capital Overseas Master Fund, Ltd., managed by Empyrean Capital Partners, LP, Medy-Tox Inc., Daewoong pharmaceutical Co.,Ltd, Strathspey Crown LLC and others in a reverse merger transaction.	22-12-12	CI
Priveterra Acquisition Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14	CI
Priveterra Acquisition Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-12	CI
Priveterra Acquisition Corp. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-12	CI
Priveterra Acquisition Corp. Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-28	CI
Priveterra Acquisition Corp. Auditor Raises 'Going Concern' Doubt	22-03-27	CI
Priveterra Acquisition Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-15	CI
Priveterra Acquisition Corp. Reports Earnings Results for the Second Quarter Ended June 30, 2021	21-08-16	CI
Certain Class B Common Stock of Priveterra Acquisition Corp. are subject to a Lock-Up Agreement Ending on 9-AUG-2021.	21-08-08	CI
Priveterra Acquisition Corp.(NasdaqCM:PMGM) added to NASDAQ Composite Index	21-04-09	CI
Priveterra Acquisition Corp. announced that it has received $7.82 million in funding from Priveterra Sponsor, LLC	21-02-10	CI
Priveterra Acquisition Corp. has completed an IPO in the amount of $240 million.	21-02-08	CI
Priveterra Acquisition Corp. has filed an IPO in the amount of $200 million.	21-01-21	CI

Chart PRIA ACQU

Duration

Period

More charts

Company Profile

AEON Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing botulinum toxin complex, ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, with a focus on the neurosciences market. ABP-450 contains a 900 kDa botulinum toxin type-A complex produced by the bacterium clostridium botulinum. The active part of the botulinum toxin is the 150 kDa component, and the remaining 750 kDa of the complex is made up of accessory proteins. When injected at therapeutic levels, ABP-450 blocks peripheral acetylcholine release at presynaptic cholinergic nerve terminals by cleaving SNAP-25, a protein integral to the docking and release of acetylcholine from vesicles situated within the nerve endings leading to denervation and relaxation of the muscle. It has completed Phase II clinical study of ABP-450 for the treatment of cervical dystonia and has an ongoing Phase II study of ABP-450 for the treatment of both chronic and episodic migraine.

Sector

More about the company